Immune escape in colorectal cancer: Mechanisms and challenges of immune checkpoint inhibitor resistance
International Immunopharmacology · 2026-01 · 169 · 115986
DOI: 10.1016/j.intimp.2025.115986 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2026-01. Verfasst von Mohammad Yousefi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Immune Checkpoint Inhibitors, Drug Resistance, Neoplasm, Tumor Escape. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 142 Literaturangaben.
Abstract (Originalsprache)
Colorectal cancer (CRC) is a leading cause of cancer-related mortality globally, with limited therapeutic success in its advanced stages. Immune checkpoint inhibitors (ICIs) are among the most significant immunotherapies in cancer treatment, revolutionizing the field. However, their effectiveness in CRC, particularly in microsatellite-stable (MSS) or proficient mismatch repair (pMMR) tumors, remains modest. This review examines the current landscape of ICI therapy in metastatic CRC, emphasizing FDA-approved agents that target PD-1, PD-L1, and CTLA-4, as well as emerging checkpoints like LAG-3 and TIM-3. In this study, we discuss key mechanisms underlying resistance to ICIs, which include factors from the tumor suppressor microenvironment, such as suppressor cells and cytokines, mechanisms of inhibiting or preventing the infiltration of effector lymphocytes, alongside tumor-intrinsic factors like defective antigen presentation, low tumor mutational burden, and activation of oncogenic pathways. Understanding these resistance mechanisms is crucial for developing effective combination strategies and improving patient outcomes. Advances in molecular profiling and immune modulation present promising opportunities to broaden the application of ICIs in the treatment of CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran.
- Department of Immunology, Faculty of Medicine, Zabol University of Medical Sciences, Zabol, Iran.
- Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran; Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran…
Zitieren
APA
Yousefi, M., Amirabadi, D. G., Javan, M. R., & Khosrojerdi, A. (2026). Immune escape in colorectal cancer: Mechanisms and challenges of immune checkpoint inhibitor resistance. International Immunopharmacology, 169, 115986. https://doi.org/10.1016/j.intimp.2025.115986
Vancouver
Yousefi M, Amirabadi DG, Javan MR, Khosrojerdi A. Immune escape in colorectal cancer: Mechanisms and challenges of immune checkpoint inhibitor resistance. International Immunopharmacology. 2026;169:115986. doi:10.1016/j.intimp.2025.115986
BibTeX
@article{Yousefi2026,
author = {Yousefi, Mohammad and Amirabadi, Danial Gharaie and Javan, Mohammad Reza and Khosrojerdi, Arezou},
title = {Immune escape in colorectal cancer: Mechanisms and challenges of immune checkpoint inhibitor resistance},
journal = {International Immunopharmacology},
year = {2026},
volume = {169},
pages = {115986},
doi = {10.1016/j.intimp.2025.115986}
}
EUVIMED